Alpha-fetoprotein concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases

被引:13
作者
Mora, J
Gascon, N
Tabernero, JM
Germa, JR
Gonzalez, F
机构
[1] HOSP SANT PAU,DEPT MED ONCOL,E-08025 BARCELONA,SPAIN
[2] UNIV BELLVITGE,CIUTAT SANITARIA,HOSP DURAN & REYNALS,DEPT MED ONCOL,BARCELONA,SPAIN
关键词
alpha-fetoprotein; concanavalin A; germ cell tumours; non-tumoral liver diseases;
D O I
10.1016/0959-8049(95)00485-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to differentiate whether slight alpha-fetoprotein (AFP) increases observed in any patient are due to germ cell tumours (GCT) or to liver diseases (including hepatotoxicity of chemotherapy), we measured the binding ratio of the AFP to concanavalin A (ConA). A total of 218 serum samples were studied: 102 samples from 72 GCT patients and 116 from patients with liver diseases. Considering a cut-off value to be a ConA binding ratio of 15%, we distinguished AFP produced by GCT (>15%) from AFP produced by tumoral and non-tumoral liver diseases (less than or equal to 15%) with a sensitivity of 98% and specificity of 100%. The difference between mean ConA binding ratios was statistically significant (P < 0.0001). We did not distinguish AFP produced by tumoral and non-tumoral liver diseases. ConA binding ratio may be a sensitive index to distinguish whether an increase of AFP concentration as low as 15 U/ml in a GCT patient during the follow-up is produced by the tumour or by liver dysfunction (including hepatotoxicity of chemotherapy).
引用
收藏
页码:2239 / 2242
页数:4
相关论文
共 13 条
[1]  
BUAMAH PK, 1984, CLIN CHEM, V30, P1257
[2]   PROBLEMS OF INTERPRETATION OF SERUM CONCENTRATIONS OF ALPHA-FETOPROTEIN (AFP) IN PATIENTS RECEIVING CYTO-TOXIC CHEMOTHERAPY FOR MALIGNANT GERM-CELL TUMORS [J].
COPPACK, S ;
NEWLANDS, ES ;
DENT, J ;
MITCHELL, H ;
GOKA, G ;
BAGSHAWE, KD .
BRITISH JOURNAL OF CANCER, 1983, 48 (03) :335-340
[3]  
GERMA JR, 1993, CANCER, V72, P2491, DOI 10.1002/1097-0142(19931015)72:8<2491::AID-CNCR2820720829>3.0.CO
[4]  
2-0
[5]   CONCANAVALIN A AFFINITY OF ALPHA-FETOPROTEIN - ITS USE IN DIFFERENTIATING TUMORS [J].
GOVINDARAJAN, S ;
FONG, TL ;
ASHCAVAI, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 88 (06) :722-724
[6]  
KUROMATSU R, 1993, LIVER, V13, P177
[7]   ALPHA-FETOPROTEIN-LECTIN BINDING AS A MARKER OF TUMOR-ACTIVITY OR LIVER-DAMAGE [J].
MARRINK, J ;
SLEIJFER, DT ;
DEVRIES, EGE ;
KOOPS, HS .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (09) :969-972
[8]  
MINGQUING D, 1991, CANCER, V67, P476
[9]   SERUM ALPHA-FETOPROTEIN LEVELS AND MICROHETEROGENEITY IN PATIENTS WITH DIFFERENT LIVER-DISEASES [J].
NIKOLIC, JA ;
STAJIC, M ;
CUPERLOVIC, M ;
HAJDUKOVIC, L ;
GOLUBOVIC, G .
JOURNAL OF HEPATOLOGY, 1990, 11 (02) :252-256
[10]   LECTIN-REACTIVE PROFILES OF ALPHA-FETOPROTEIN CHARACTERIZING HEPATOCELLULAR-CARCINOMA AND RELATED CONDITIONS [J].
TAKETA, K ;
SEKIYA, C ;
NAMIKI, M ;
AKAMATSU, K ;
OHTA, Y ;
ENDO, Y ;
KOSAKA, K .
GASTROENTEROLOGY, 1990, 99 (02) :508-518